

i.e. that postzygotic mutations in other genes may cause similar phenotypes. The mechanism explaining how different phenotypes, heterochromia of the scalp and woolly hair naevus are caused by the same mutation requires gene expression studies at a single-cell level.

<sup>1</sup>Department of Dermatology, Medical Center  
- University of Freiburg, Faculty of  
Medicine, Freiburg, Germany

<sup>2</sup>Institute for Human Genetics, Medical  
Center - University of Freiburg, Freiburg,  
Germany

C. HAS<sup>1</sup> 

R. HAPPLE<sup>1</sup>

J. FISCHER<sup>2</sup>

G. GRÜNINGER<sup>1</sup>

K. TECHNAU-HAFSI<sup>1</sup>

## References

- Restano L, Barbareschi M, Cambiaghi S et al. Heterochromia of the scalp hair: a result of pigmentary mosaicism? *J Am Acad Dermatol* 2001; **45**:136–9.
- Iorizzo M, Piraccini BM, Tosti A. Heterochromia of the scalp hair following Blaschko lines. *Pediatr Dermatol* 2007; **24**:69–70.
- Bonamonte D, Filoni A, Vestita M et al. Scalp hair heterochromia in a 5-year-old child: rare somatic mosaicism? *Pediatr Dermatol* 2014; **31**:733–4.
- Kocak AY, Kocak O, Bonamonte D et al. Heterochromia of the scalp hair following Blaschko lines: four cases. *Pediatr Dermatol* 2015; **32**:740–1.
- Happle R. *Mosaicism in human skin*. Berlin: Heidelberg, Springer-Verlag, 2014.
- Groesser L, Herschberger E, Ruetten A et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. *Nat Genet* 2012; **44**:783–7.
- Levinsohn JL, Teng J, Craiglow BG et al. Somatic HRAS p.G12S mutation causes woolly hair and epidermal nevi. *J Invest Dermatol* 2014; **134**:1149–52.
- Nishimura EK. Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. *Pigment Cell Melanoma Res* 2011; **24**:401–10.

Funding sources: none.

Conflicts of interest: none to declare.

## Finalizing the international core domain set for peripheral vascular malformations: the OVAMA project

DOI: 10.1111/bjd.18043

DEAR EDITOR, There is a variety of outcome reporting in the clinical research on peripheral vascular malformations,<sup>1–3</sup> including capillary, venous, lymphatic, arteriovenous and combined malformations. Without harmonization of outcome measures, treatments cannot be properly compared. This hampers the development of evidence-based treatment guidelines, urgently needed for these challenging congenital conditions. The mission of the Outcome measures for Vascular

Malformations (OVAMA) project is to uniform outcome reporting in clinical research.

To evaluate treatment efficacy, the first step is deciding on what to measure. In a previous study, we developed a core domain set (CDS) for peripheral vascular malformations, excluding capillary malformations.<sup>4</sup> A CDS is a minimum set of outcome domains that should be measured when evaluating treatment outcomes in health conditions.<sup>5</sup> This international consensus project, involving 167 physician and 134 patient/parent contributors, consisted of a three-round e-Delphi study and an online consensus meeting. For some domains consensus was not achieved, specifically ‘recurrence’, ‘appearance’, ‘radiological imaging’ and ‘lymphatic fluid leakage’.<sup>4</sup> A face-to-face consensus meeting was organized to establish the final CDS.

As an addendum to the previous study, this letter describes the conclusions of this face-to-face meeting and reports the final CDS for peripheral vascular malformations.

The meeting was chaired by the then coordinator of the OVAMA project, and was held at the International Society for the Study of Vascular Anomalies (ISSVA) conference (28 May to 1 June 2018) in Amsterdam, the Netherlands. All previous study participants (n = 301)<sup>4</sup> were invited to join. Participants included 26 experts of the OVAMA Consensus Group; 85% represented various medical specialities (surgery, otolaryngology, paediatrics, paediatric haematology/oncology, radiology and dermatology) and 15% were patient organization representatives.

An overview of the e-Delphi and online consensus meeting results was sent to all participants beforehand, and printed summaries were provided. The undecided domains were then separately discussed by the whole group and a final consensus reached. In order to reach different results than in the online consensus meeting, group unanimity on including/dropping/changing each outcome domain was required before proceeding to the next. The final CDS is presented in Figure 1.

The provisionally included domain ‘recurrence’ was excluded from the final CDS, as participants agreed that it was a reflection of other domains rather than a distinct domain.

The domain ‘appearance’, defined as the visible anatomical characteristics of the vascular malformation such as size, colour and texture, was excluded from the e-Delphi study; however, it was considered essential during the online consensus meeting. Participants noted during the e-Delphi study that ‘appearance’ may be confused with ‘body image’. As ‘appearance’ often initiates treatment, participants suggested that it should be incorporated in the final CDS. As it was considered relevant from both the patient’s and the clinician’s perspective, ‘appearance’ was included as a patient-reported and clinician-reported core domain.

‘Radiological imaging’ was found to be the instrument by which the radiological characteristics are evaluated, so this domain was changed to ‘radiological characteristics’. Because follow-up radiological imaging is not routinely performed in all cases, the domain ‘radiological characteristics’ was not considered obligatory, and was hence excluded from the final




Fig. 1. Core domain set for peripheral vascular malformations. Domain categories and domains were based on the classification as reported in Appendix S2 of the previously published core outcome set development study (Horbach SER, van der Horst C, Blei F et al. Development of an international core outcome set for peripheral vascular malformations: the OVAMA project. *Br J Dermatol* 2018; **178**: 473–81). <sup>a</sup>Only relevant at follow-up. AVM, only for arteriovenous malformations, LM, only for lymphatic malformations, VM, only for venous malformations.

CDS. However, if radiological imaging is performed before and after treatment, it should be reported.

The group concluded that diagnosing 'lymphatic fluid leakage' requires medical knowledge that cannot be expected of patients. Consequently, it was moved from the patient-reported 'symptoms' to the 'clinician-reported 'signs' in the final CDS.

The general opinion of the group was that the domain categories 'patient satisfaction' and 'adverse events' should be included in the final CDS, but were only relevant after treatment has started, and therefore should only be measured at follow-up.

No other domains or discussion points were left unresolved.

With this face-to-face consensus meeting, we successfully finalized the CDS for clinical research in peripheral vascular malformations (Fig. 1).

As measurement of these domains does not require invasive or costly techniques, measurement of the relatively high number of domains is still considered feasible. By including many international experts in the field and patients, this process ensured a diversity of perspectives. The face-to-face set-up and information provided beforehand enabled in-depth discussion and enhanced participant engagement. An unavoidable limitation was that only stakeholders present at the ISSVA conference were able to participate.

This project represents a significant step towards meaningful assessment and comparison of treatments for peripheral vascular malformations. The next step towards uniform outcome reporting is determining how to measure these core

domains, i.e. developing a core outcome measurement set. This project, involving an appraisal of available instruments and development of a new disease-specific instrument, is currently being carried out by the OVAMA Steering Group.

<sup>1</sup>Department of Plastic, Reconstructive and Hand Surgery, Amsterdam University

M.M. LOKHORST<sup>1</sup>

S.E.R. HORBACH<sup>1</sup>

Medical Centers, University of Amsterdam, the Netherlands

C.M.A.M. van der HORST<sup>1</sup>

P.I. SPULS<sup>2</sup>

<sup>2</sup>Department of Dermatology, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands

On behalf of the

OVAMA Steering Group

E-mail: m.m.lokhorst@amc.uva.nl

S.E.R. Horbach was OVAMA project coordinator during this study.

A full list of the OVAMA Steering Group collaborators is provided in Appendix S1 (see Supporting Information).

## References

- Horbach SE, Lokhorst MM, Saeed P et al. Sclerotherapy for low-flow vascular malformations of the head and neck: a systematic review of sclerosing agents. *J Plast Reconstr Aesthet Surg* 2016; **69**:295–304.
- Horbach SE, Rigter IM, Smitt JH et al. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. *Plast Reconstr Surg* 2016; **137**:244–56.
- Langbroek GB, Horbach SE, van der Vleuten CJ et al. Compression therapy for congenital low-flow vascular malformations of the extremities: a systematic review. *Phlebology* 2018; **33**:5–13.

- 4 Horbach SER, van der Horst C, Blei F et al. Development of an international core outcome set for peripheral vascular malformations: the OVAMA project. *Br J Dermatol* 2018; **178**:473–81.
- 5 Boers M, Kirwan JR, Wells G et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol* 2014; **67**:745–53.

Funding sources: none.

Conflicts of interest: none to declare.

### Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

**Appendix S1** OVAMA SteeringGroup collaborators.

## Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study

DOI: 10.1111/bjd.18090

DEAR EDITOR, Approval of the etanercept biosimilar SB4 (Brenzys/Benepali; Samsung Bioepis Co., Ltd.) for psoriasis and psoriatic arthritis (PsA) was automatically obtained on the basis of the demonstration of quality, biological activity, efficacy, safety and immunogenicity similarity to the reference etanercept in the treatment of rheumatoid arthritis.<sup>1,2</sup> As the development of biosimilars is a significant opportunity to




Fig 1. (a) Psoriasis Area and Severity Index for patients with plaque-type psoriasis or psoriatic arthritis. (b) Improvement in scores from baseline to week 24. Pain-VAS scores in the chart have been divided by 10. DAS28-ESR Disease Activity Score for 28 joints–erythrocyte sedimentation rate; SJC, swollen joint count; TJC, tender joint count; pain VAS, visual analogue scale for pain.